Amgen Profit Rises as Enbrel Sales Offset Anemia Fall
This article is for subscribers only.
Amgen Inc., the world’s largest biotechnology company, said fourth-quarter profit rose 9.8 percent on rising sales of its top two drugs, Neulasta and Enbrel, and lowered expenses for research and taxes.
Net income rose to $1.02 billion, or $1.08 a share, from $931 million, or 92 cents a share, a year ago, the Thousand Oaks, California-based company said in a statement. Excluding certain costs, earnings of $1.17 per share beat the $1.11 average estimate of 23 analysts surveyed by Bloomberg.